Treatment of prosthetic tricuspid valve thrombosis with recombinant tissue-type plasminogen activator.
Recombinant tissue-type plasminogen activator (rt-PA) was administered intravenously to a 64-years old female with thrombotic malfunction of a Björk-Shiley prosthetic tricuspid valve. 150 mg of single-chain rt-PA was infused over 8 hours followed by an additional dose of 50 mg over the next 8 hours. At the end of the first infusion, restoration of normal valve function was demonstrated by fluoroscopic and echo-Doppler examinations. Mild systemic activation of the fibrinolytic system occurred, with a decrease of fibrinogen and alpha 2-antiplasmin to 53% and 33%, respectively, of the preinfusion value at the nadir.
D005260:Female; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D006487:Hemostasis; D006801:Humans; D008875:Middle Aged; D011475:Prosthesis Failure; D013927:Thrombosis / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014261:Tricuspid Valve / Q000601:surgery
D010959:Tissue Plasminogen Activator